Hanmi Pharmaceutical reported a 116.9% increase in second-quarter operating profit, driven by global technology transfer achievements and growth in its domestic pharmaceutical business.
On July 28, Hanmi announced its preliminary consolidated results for the second quarter of 2026, showing revenue of 467.2 billion won and operating profit of 131.1 billion won. Compared to the same period last year, revenue increased by 29.3%, and operating profit rose by 116.9%. The company recorded a net profit of 84.1 billion won for the quarter, a 95.5% increase. It invested 60.3 billion won, or 12.9% of its revenue, in research and development (R&D).
For the first half of the year, Hanmi's cumulative consolidated revenue reached 860.2 billion won, a 14.4% increase from the same period last year, while operating profit rose by 54.6% to 184.7 billion won.
Hanmi stated, "The solid growth of key products like Rosuzet, increased sales through joint marketing with global pharmaceutical companies, and the recognition of the technology transfer contract fee from Eli Lilly for sonepaglutide have driven our performance improvement. We expect to achieve the highest revenue in our history this year."
According to Ubiest, the company's revenue from external prescriptions in the first half was 561.6 billion won. Hanmi has maintained its position as the top company in South Korea's external prescription sales for eight consecutive years since 2018.
Hanmi's subsidiary, Beijing Hanmi Pharmaceutical, reported second-quarter revenue of 60.7 billion won. Due to China's centralized purchasing system, which favors the lowest bidders, revenue and operating profit decreased compared to the same period last year. The company plans to secure new growth engines through the development of non-centralized purchasing items and new drugs.
Hanmi Precision Chemical, a subsidiary specializing in active pharmaceutical ingredients (APIs), recorded second-quarter revenue of 24 billion won, a 4.4% increase year-on-year. The growth was supported by increased exports of APIs to Japan and expanded high-profit contract development and manufacturing (CDMO) orders, leading to a 76.7% rise in operating profit compared to the previous year.
The company is preparing for the commercialization of its glucagon-like peptide-1 (GLP-1) obesity treatment, epeglanatide, within the year. Additionally, its next-generation obesity treatment, HM15275, is in Phase 2 clinical trials in the U.S., while HM17321, aimed at treating obesity through muscle gain, has entered Phase 1 clinical trials.
Hanmi CEO Hwang Sang-yeon stated, "We will continue to enhance corporate value through responsible management and continuous innovation, creating new opportunities for growth."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.